153 related articles for article (PubMed ID: 32669932)
1. Does the time from diagnostic biopsy to neoadjuvant chemotherapy affect the rate of pathologic complete response in stages I-III breast cancer?
Le D; Eslami M; Li H; Hajjaj O; Chia S; Simmons C
Curr Oncol; 2020 Jun; 27(3):e265-e270. PubMed ID: 32669932
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses.
Yang Y; Im SA; Keam B; Lee KH; Kim TY; Suh KJ; Ryu HS; Moon HG; Han SW; Oh DY; Han W; Kim TY; Park IA; Noh DY
BMC Cancer; 2016 Jul; 16():515. PubMed ID: 27444430
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy.
Kim H; Park W; Huh SJ; Choi DH; Noh JM; Im YH; Ahn JS; Park YH; Nam SJ; Kim SW; Lee JE; Cho EY
Asia Pac J Clin Oncol; 2017 Aug; 13(4):329-336. PubMed ID: 27869361
[TBL] [Abstract][Full Text] [Related]
4. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
[TBL] [Abstract][Full Text] [Related]
5. Impact of wait time from neoadjuvant chemotherapy to surgery in breast cancer: Does time to surgery affect patient outcomes? : Time from Neoadjuvant Chemotherapy to Surgery.
Lai V; Hajjaj O; Le D; Shokoohi A; Chia S; Simmons C
Breast Cancer Res Treat; 2020 Dec; 184(3):755-762. PubMed ID: 33001336
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy.
Asaoka M; Narui K; Suganuma N; Chishima T; Yamada A; Sugae S; Kawai S; Uenaka N; Teraoka S; Miyahara K; Kawate T; Sato E; Nagao T; Matsubara Y; Gandhi S; Takabe K; Ishikawa T
Eur J Surg Oncol; 2019 Dec; 45(12):2289-2294. PubMed ID: 31787153
[TBL] [Abstract][Full Text] [Related]
7. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
[TBL] [Abstract][Full Text] [Related]
8. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
9. MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer.
Weber JJ; Jochelson MS; Eaton A; Zabor EC; Barrio AV; Gemignani ML; Pilewskie M; Van Zee KJ; Morrow M; El-Tamer M
J Am Coll Surg; 2017 Dec; 225(6):740-746. PubMed ID: 28919579
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes after breast conserving surgery.
Woeste MR; Bhutiani N; Donaldson M; McMasters KM; Ajkay N
J Surg Oncol; 2021 Feb; 123(2):439-445. PubMed ID: 33259649
[TBL] [Abstract][Full Text] [Related]
11. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.
Goorts B; van Nijnatten TJ; de Munck L; Moossdorff M; Heuts EM; de Boer M; Lobbes MB; Smidt ML
Breast Cancer Res Treat; 2017 May; 163(1):83-91. PubMed ID: 28205044
[TBL] [Abstract][Full Text] [Related]
12. Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy?
Daveau C; Stevens D; Brain E; Berges O; Villette S; Moisson P; Gardner M; De la Lande B; Lasry S; Labib A; Le Scodan R
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):337-42. PubMed ID: 20171795
[TBL] [Abstract][Full Text] [Related]
13. Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy.
Choi HJ; Ryu JM; Kim I; Nam SJ; Kim SW; Yu J; Lee JE; Lee SK
Breast Cancer Res Treat; 2019 Aug; 176(3):591-596. PubMed ID: 31065874
[TBL] [Abstract][Full Text] [Related]
14. Refining the indications for neoadjuvant chemotherapy for patients with HER2+ breast cancer: A single institution experience.
Pomponio MK; Burkbauer L; Goldbach M; Nazarian SM; Xie F; Clark AS; Matro JM; Fox KR; Shulman LN; Keele LJ; Tchou J
J Surg Oncol; 2020 Mar; 121(3):447-455. PubMed ID: 31919848
[TBL] [Abstract][Full Text] [Related]
15. Variation in use of neoadjuvant chemotherapy in patients with stage III breast cancer: Results of the Dutch national breast cancer audit.
Spronk PER; van Bommel ACM; Siesling S; Wouters MWJM; Vrancken Peeters MTFD; Smorenburg CH
Breast; 2017 Dec; 36():34-38. PubMed ID: 28942098
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy Use for Nonmetastatic Breast Cancer at Five Public South African Hospitals and Impact on Time to Initial Cancer Therapy.
O'Neil DS; Nietz S; Buccimazza I; Singh U; Čačala S; Stopforth LW; Joffe M; Jacobson JS; Neugut AI; Crew KD; Ruff P; Cubasch H
Oncologist; 2019 Jul; 24(7):933-944. PubMed ID: 30518615
[TBL] [Abstract][Full Text] [Related]
17. Effect of Body Mass Index- and Actual Weight-Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer.
Raman R; Mott SL; Schroeder MC; Phadke S; El Masri J; Thomas A
Clin Breast Cancer; 2016 Dec; 16(6):480-486. PubMed ID: 27431461
[TBL] [Abstract][Full Text] [Related]
18. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.
Tadros AB; Yang WT; Krishnamurthy S; Rauch GM; Smith BD; Valero V; Black DM; Lucci A; Caudle AS; DeSnyder SM; Teshome M; Barcenas CH; Miggins M; Adrada BE; Moseley T; Hwang RF; Hunt KK; Kuerer HM
JAMA Surg; 2017 Jul; 152(7):665-670. PubMed ID: 28423171
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
[TBL] [Abstract][Full Text] [Related]
20. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
White R; Dinneen T; Makris A
Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
